98%
921
2 minutes
20
Simple prostatectomy (SP) and laser enucleation of the prostate (LEP) are treatments for symptomatic benign prostatic hyperplasia (BPH) in men with large glands (e.g., >80 g). The decision between the two operations is often dependent on surgeon preference/experience and equipment availability. As the use of minimally invasive techniques, such as robotic-assisted simple prostatectomy, has increased for the treatment of large gland BPH, studies comparing the outcomes and cost of these modalities in a contemporary cohort are lacking. All-payer data from Healthcare Cost and Utilization Project State Databases from Florida, New York, California, and Maryland from 2016 to 2018 were used to identify adults who underwent SP or LEP for BPH. Patient demographics, facility characteristics, revisit rates, and cost of the index hospitalization were examined. Multivariable logistic and gamma generalized linear regression models were utilized to compare predictors of the operation performed, 30-day revisits, and index hospitalization cost among the two operations. Of the 2032 patients in the cohort, 1067 (46.4%) underwent LEP and 965 (41.9%) underwent SP. On multivariable logistic regression analysis, SP patients were younger, had higher comorbidity scores, and were more likely to be uninsured compared with LEP patients. Thirty-day revisit rates among the operations were equivalent (odds ratio 0.89, 95% confidence interval 0.63-1.27, = 0.05). The mean adjusted cost of the index hospital stay for LEP was significantly greater than that of SP ($7291 $6442, = 0.04). However, our sub-group analysis examining high-volume centers revealed no significant differences in cost ($6184 $5353, = 0.1). Across the four states examined, SP and LEP were performed with comparable volume and had similar rates of 30-day revisits. The SP was less expensive than LEP overall; however, among high-volume facilities, the cost of both operations was reduced, such that they were equivalent.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1089/end.2022.0404 | DOI Listing |
Can J Urol
August 2025
Department of Urology, Duke University Hospital, Durham, NC 27710, USA.
Background: Radical prostatectomy has long been the treatment of choice for men with clinically significant prostate cancer (PCa) in those with concurrent significant lower urinary tract symptoms (LUTS). For men who meet this description with marked prostatomegaly, we present a multi-institutional proof of concept study describing an alternative pathway of robotic simple prostatectomy (RASP) followed by external beam radiation therapy (EBRT) for the treatment of clinically significant prostate cancer.
Methods: A retrospective study was performed of 17 patients with PCa who underwent RASP followed by EBRT at two institutions from 2015-2023.
Aims: The aim of this study was to develop and verify a new emergence agitation risk prediction model based on the electronic medical records of patients undergoing transurethral resection of the prostate.
Background: The incidence of prostate disease in elderly men is high, and the harm caused by emergence agitation in patients after transurethral resection of the prostate is serious. It is necessary to develop a predictive model for emergence agitation in patients undergoing transurethral resection of the prostate.
Urol Res Pract
July 2025
Department of Urology, Shahid Beheshti University of Medical Sciences, Shahid Modarress Hospital, Tehran, Iran.
Objective: This retrospective cross-sectional study aimed to compare functional and surgical outcomes after open simple prostatectomy (OSP) between patients who underwent prior transurethral resection of the prostate (TURP) and those who did not. Methods: Between March 2009 and April 2019, 723 patients underwent TURP, of whom 20 (2.7%) subsequently underwent OSP (Group 1).
View Article and Find Full Text PDFJ Robot Surg
August 2025
Department of Urology, Affiliated Hospital of North Sichuan Medical College, No. 1 Mao Yuan South Road, Wenhua Road 57, Shunqing, Nanchong, 637000, Sichuan, People's Republic of China.
With the rising prevalence of benign prostatic hyperplasia (BPH), there is an increasing demand for surgical interventions that optimize patient outcomes while minimizing complications. This systematic review aims to critically evaluate and contrast the clinical outcomes, surgical efficiency, and safety profiles during the perioperative period for holmium laser enucleation of the prostate (HoLEP) and robot-assisted simple prostatectomy (RASP) in patients diagnosed with BPH exhibiting a prostate volume of ≥ 80 mL, providing evidence-based insights for BPH management. Adhering to the EAU Guidelines Office and PRISMA guidelines, the study protocol was registered with Prospero [CRD420251059418].
View Article and Find Full Text PDFJ Endourol
August 2025
The James Buchanan Brady Urological Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Short-term outcomes of Aquablation as the treatment for benign prostatic hyperplasia (BPH) have not been well characterized. The aim of this analysis was to compare rates of 30- and 90-day complications following Aquablation with those after transurethral resection of prostate (TURP), UroLift, holmium laser enucleation of the prostate (HoLEP), and laparoscopic simple prostatectomy (SP). Using the TriNetX Research database, a collaborative claims and electronic medical record research network of 79 large health care organizations, we conducted a propensity-matched retrospective cohort study of all patients who underwent Aquablation (Current Procedural Terminology [CPT] 0421T or Healthcare Common Procedure Coding System ((HCPCS) C2596), TURP (CPT 52601), UroLift (CPT 52441), HoLEP (CPT 52649), or laparoscopic SP (CPT 55866, 55867) between the dates of January 1, 2017, and December 31, 2023.
View Article and Find Full Text PDF